| Bioactivity | KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine[1]. |
| Invitro | KRAS G13D peptide, 25 mer is encoded by immunomodulatory therapeutic mRNA that can be used to prepare KRAS vaccine[1]. |
| Name | KRAS G13D peptide, 25 mer |
| CAS | 145019-94-9 |
| Sequence | Met-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-Gly-Asp-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-Leu-Ile-Gln |
| Shortening | MTEYKLVVVGAGDVGKSALTIQLIQ |
| Formula | C118H201N29O36S |
| Molar Mass | 2634.10 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
KRAS G13D peptide, 25 mer
CAS: 145019-94-9 F: C118H201N29O36S W: 2634.10
KRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent W
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.